Haystack Oncology and Université de Montréal’s affiliated hospital research centre, the CRCHUM, to deploy Haystack MRD™ technology in study for metastatic colorectal cancer. Read the full press release at hubs.ly/Q02Jg4xl0 #PrecisionOncology #CancerResearch

In an update to the DYNAMIC study presented at the #ASCO24 meeting by Dr Jeanne Tie, #ctDNA testing continued to be a significant predictor of survival at the 5-year mark. Learn more at hubs.la/Q02CtTz30

Haystack Oncology and Université de Montréal’s affiliated hospital research centre, the CRCHUM, to deploy Haystack MRD™ technology in study for metastatic colorectal cancer. Read the full press release at hubs.ly/Q02Jg9Cb0 #PrecisionOncology #CancerResearch

Haystack Oncology and Université de Montréal’s affiliated hospital research centre, the CRCHUM, to deploy Haystack MRD™ technology in study for metastatic colorectal cancer. Read the full press release at hubs.la/Q02JMZf70 #PrecisionOncology #CancerResearch

Haystack’s #ctDNA testing was the fastest indicator of cCR among various detection methods explored in a recent rectal cancer study, detecting clinical response around 4.8 months faster than endoscopy or rectal MRI. Learn more at hubs.la/Q02M3Gy_0

We’ve published the first-ever budget analysis for using ctDNA-based minimal residual disease (#MRD) testing to guide adjuvant therapy decisions. #ctDNA testing in patients with stage II #colorectalcancer was projected to reduce total healthcare costs hubs.la/Q02M3GKt0

Unlocking the potential of ctDNA-based MRD testing to improve cancer management— insights from Haystack's Director of Medical Affairs, Dr Hillary Sloane hubs.la/Q02M3HBf0

In an update to the DYNAMIC study presented at the #ASCO24 meeting by Dr Jeanne Tie, #ctDNA testing continued to be a significant predictor of survival at the 5-year mark. Learn more at hubs.la/Q02M3Gws0

Happy to announce that we’ll be attending #ESMO24 in Barcelona! Join us at Quest Diagnostics booth 637 to learn how Haystack’s advanced ctDNA detection can elevate your oncology research with targeted patient selection and ultrasensitive cancer monitoring hubs.la/Q02N_tH00

Using #ctDNA-based #MRD testing to guide adjuvant therapy decisions in stage II #colorectalcancer patients can reduce total healthcare costs, according to our budget analysis published in JAMA Health Forum hubs.la/Q02M3Hgf0

Looking forward to connecting with industry leaders at #ESMO24! Visit the Quest Diagnostics booth (637) to learn how Haystack’s ultrasensitive #ctDNA detection technology can revolutionize care for patients diagnosed with solid tumors hubs.la/Q02N_CJT0 #ESMO24 #MRD

Heading to #FSPxFLASCO? Join us in Tampa Sept 13-14 and catch the roundtable on molecular diagnostics on Sept 14! Let's advance #Oncology together. hubs.la/Q02Ppk7G0 #FSPxFLASCO2024 #FSP #FLPathConf #FLASCO

Excited to be part of #FSPxFLASCO2024 in Tampa, FL on Sept 13-14! Join us on Sept 14 from 1:00 PM to 2:00 PM for a roundtable on #MolecularDiagnostics that includes Dr Mark Kruzel, medical director of Oncology at Quest Diagnostics hubs.la/Q02Ppp190 #FSP #FLPathConf #FLASCO

We’re attending #ESMO24 in Barcelona September 13-17! Visit the Quest Diagnostics booth (637) to learn more about Haystack MRD™ ultrasensitive #ctDNA detection. hubs.la/Q02N_By60

Heading to the 2024 ESMO Congress in Barcelona? So are we! Visit the Quest Diagnostics booth (637) to meet the Haystack team and learn about our ultrasensitive #ctDNA-based minimal residual disease testing. Learn more at hubs.la/Q02N_CY90 #MRD #ESMO24 #ctDNA

Join us at #FSPxFLASCO in Tampa! Dr Mark Kruzel, medical director of Oncology at Quest Diagnostics, will be part of the roundtable discussion on #MolecularDiagnostics on Sept 14, 1:00 PM to 2:00 PM. Don’t miss it! hubs.la/Q02Ppph00 #FSPxFLASCO2024 #FSP #FLASCO #CancerCare

We’re excited to connect with potential #biopharma collaborators at #ESMO24 in Barcelona! Visit the Quest Diagnostics booth (637) to discover how Haystack’s ultrasensitive ctDNA detection can advance your oncology research. Learn more at hubs.la/Q02N_yKs0

We're excited to have Dr Mark Kruzel, medical director of Oncology at Quest Diagnostics, participate in the #FSPxFLASCO roundtable on #MolecularDiagnostics, Sept 14th from 1:00 PM to 2:00 PM. Don't miss it! hubs.la/Q02Ppprk0 #FSPxFLASCO2024 #FSP #FLASCO #Oncology

Don’t miss Haystack at the 2024 ESMO Congress! Visit the Quest Diagnostics booth (637) to say hello and learn about our ultrasensitive minimal residual disease testing. #MRD #ctDNA #cancerresearch #ESMO24 hubs.la/Q02N_BDL0

Looking forward to connecting with industry leaders at #ESMO24! Visit the Quest Diagnostics booth (637) to learn how Haystack’s ultrasensitive #ctDNA detection technology can revolutionize care for patients diagnosed with solid tumors hubs.la/Q02Py1R80 #ESMO24 #MRD